Pharmacokinetics/pharmacodynamics (PK/PD) of the novel, first-in-class glycosylphosphatidylinositol (GPI) Inhibitor APX001 in the neutropenic murine invasive candidiasis model against C. albicans (CA), C. glabrata, and C. auris (CAU)

ECCMID 2018

Candida auris is highly in vitro susceptible to APX001A in EUCAST antifungal susceptibility testing

ECCMID 2018

Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis

ID Week 2017

Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A

ID Week 2017

Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris

ID Week 2017

APX001 Protects Immunosuppressed Mice from Rhizopus delemar Infection

ID Week 2017

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001A

ID Week 2017

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

ID Week 2017

Absorption, Distribution, and Excretion of [14C]-APX001 after Single-Dose Administration to Rats and Monkeys

ID Week 2017

In vitro activity of APX001A and comparators against clinical isolates of rare moulds

ECCMID 2017

* = submitted

Amplyx © Copyright 2018